Rhode Island Hospital | Brown Dermatology Research - Clinical Trials Unit

Research site

(Unclaimed)

Location

593 Eddy Street Jane Brown South Room 115, Providence, Rhode Island, United States of America

Site insights

Top conditions

Top treatments

cyclophosphamide

Carboplatin

ABBV-8E12

doxorubicin hydrochloride

vincristine sulfate

Mosunetuzumab

Linaclotide

Methylphenidate

Azithromycin

ABBV-916

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

14 of 96 total trials

A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors

This is a Phase 1 study to assess the safety and clinical activity of RO7623066 alone and in combination in patients with advanced solid tumors.

Enrolling

Advanced Solid Tumors

Drug: RO7623066

Drug: Olaparib

A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer

This is a multi-site, open-label, Phase II, randomized, trial to compare the efficacy of RO7198457 versus watchful waiting in patients with circulati...

Enrolling

Colorectal Cancer Stage III

Colorectal Cancer Stage II

Drug: RO7198457 intravenous (IV)

Other: Observational group (no intervention)

A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer (EMBER-4)

The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cance...

Enrolling

Breast Neoplasms

Drug: Anastrozole

Drug: Tamoxifen

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN-CLL-314)

The purpose of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL. Participants...

Active, not recruiting

Leukemia, B-cell

Small Lymphocytic Lymphoma

Drug: Pirtobrutinib

Drug: Ibrutinib

A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease

Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population. Cli...

Active, not recruiting

Alzheimer's Disease (AD)

Drug: Placebo

Drug: ABBV-916

A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (AD Up)

The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of ado...

Invitation-only

Atopic Dermatitis

Drug: Placebo

Drug: Upadacitinib

A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS

The study (dose escalation/expansion) is being conducted to assess the safety and tolerability of SHR-A1904 in subjects with advanced solid tumors, a...

Enrolling

Advanced Solid Tumors

Drug: SHR-A1904

Assessment of the GORE® EXCLUDER® Conformable AAA Endoprosthesis in the Treatment of Abdominal Aortic Aneurysms

The purpose of the study is to assess the safety and effectiveness of the GORE® EXCLUDER® Conformable AAA Endoprosthesis to treat an infrarenal aneur...

Active, not recruiting

Aortic Aneurysm, Abdominal

Device: GORE® EXCLUDER® Conformable AAA Endoprosthesis

Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present with Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF): the CORCINCH-HF Study

Prospective, randomized, open-label, international, multi-center clinical study to evaluate the safety and efficacy of the AccuCinch Ventricular Rest...

Enrolling

Heart Failure with Reduced Ejection Fraction (HFrEF)

Dilated Cardiomyopathy

Device: AccuCinch Ventricular Restoration System

Drug: Guideline-Directed Medical Therapy

Clinical Study of the Treovance Stent-Graft for Patients With Abdominal Aortic Aneurysms

The purpose of this clinical trial is to assess and evaluate the safety and efficacy of the Treovance Stent-Graft with Navitel Delivery System in sub...

Active, not recruiting

Abdominal Aortic Aneurysm (AAA)

Device: Subjects who receive the Treovance stent-graft

Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C

LIN-MD-66 is a Phase 3 open-label study with 24 weeks (Functional Constipation participants) or 52 weeks (Irritable bowel syndrome with constipation...

Active, not recruiting

Functional Constipation

Irritable Bowel Syndrome With Constipation

Drug: Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)

Drug: Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 completers)

Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM

A randomized Phase II clinical trial will be conducted to assess the impact on progression free survival (PFS) with the addition of ixazomib and dara...

Active, not recruiting

Myeloma, Multiple

Drug: Ixazomib

Drug: Daratumumab Injection

Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure (TAVR UNLOAD)

The objective of this study is to determine the safety and efficacy of transcatheter aortic valve replacement (TAVR) via a transfemoral approach in H...

Active, not recruiting

Aortic Valve Stenosis

Biological: Optimal Heart Failure Therapy

Device: SAPIEN 3 THV

Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma

This study will evaluate the safety, pharmacokinetics, and preliminary efficacy of mosunetuzumab following first-line diffuse large B-cell lymphoma (...

Active, not recruiting

Diffuse Large B-cell Lymphoma

Drug: Polatuzumab Vedotin

Drug: Mosunetuzumab Intravenous (IV)